JNJ vs PFE Stock Comparison: AI Score, Valuation, Performance and Upside
J&J and Pfizer are both large-cap pharma stalwarts but occupy very different investment narratives in 2024. J&J is a steady compounder diversified across pharma and medical devices with a prized dividend history, while Pfizer is a turnaround story rebuilding its revenue base after a massive COVID-driven boom-and-bust cycle. The choice between them is essentially stability and consistency (JNJ) versus higher risk and potential recovery upside (PFE).
Investors should evaluate whether they want J&J's proven dividend compounding and pipeline stability or Pfizer's deep valuation discount and recovery potential — the two companies are at very different points in their earnings cycles.
PFE holds the edge across 3 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+49.88% vs +5.04%), though PFE trades at the lower forward P/E (9.26x vs 18.94x). On fundamentals, JNJ is growing revenue faster (9.90%), while PFE maintains the higher operating margin (31.62%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for PFE (+11.36%) than for JNJ (+4.98%).
- →prioritize long-term dividend income with 60+ years of consecutive increases
- →want balanced healthcare exposure across pharma and medical devices
- →prefer steady pipeline execution over binary pipeline bets
- →are comfortable with modest growth in exchange for lower volatility
- →seek a contrarian bet on post-COVID revenue recovery at a discounted valuation
- →value deep pipeline optionality including the Seagen oncology platform
- →are willing to accept near-term earnings pressure for potential medium-term upside
- →want high dividend yield while the turnaround thesis plays out
| Metric | JNJ | PFE |
|---|---|---|
| AI score | 48.7 | 40.3 |
| AI rank | #544 | #1063 |
| Latest close | $228.39 | $25.21 |
| 1M return | -0.70% | -1.75% |
| 6M return | +8.59% | +0.68% |
| 1Y return | +49.88% | +5.04% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | JNJ | PFE |
|---|---|---|
| 1Y ago | $15.15K (+51.5%) started 2025-06-18 | $10.56K (+5.6%) started 2025-06-18 |
| 5Y ago | $17.38K (+73.8%) started 2021-06-21 | $9.5K (-5.0%) started 2021-06-21 |
| 10Y ago | $32.67K (+226.7%) started 2016-06-20 | $17.75K (+77.5%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
| Metric | JNJ | PFE |
|---|---|---|
| Market cap | $579.83B | $149.38B |
| Trailing P/E | 27.94 | 20.01 |
| Forward P/E | 18.94 | 9.26 |
| Price/Sales | 4.18 | 2.13 |
| EV/Revenue | 6.36 | 3.18 |
| Analyst target | $252.87 | $29.19 |
| Target upside | +4.98% | +11.36% |
| Metric | JNJ | PFE |
|---|---|---|
| Revenue growth | 9.90% | 5.40% |
| Earnings growth | -52.90% | -10.10% |
| EPS growth | -52.90% | -10.10% |
| FCF margin | +12.98% | +19.55% |
| Operating margin | 27.41% | 31.62% |
| Profit margin | 21.83% | 11.83% |
| ROIC proxy | 26.42% | 8.31% |
| Return on equity | 26.42% | 8.31% |
| Dividend yield | 2.23% | 6.56% |
| Beta | 0.26 | 0.29 |
| Debt/equity | 67.73 | 71.60 |
| Current ratio | 1.02 | 1.25 |
| Quick ratio | 0.69 | 0.85 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | JNJ | PFE |
|---|---|---|---|
| 1Y | Growth | +51.52% | +5.57% |
| CAGR | +51.61% | +5.58% | |
| Sharpe ratio | 2.26 | 0.16 | |
| Max drawdown | 10.96% | 11.70% | |
| Max daily drop | 2.48% | 3.98% | |
| Max wkly drop | 5.81% | 9.46% | |
| 5Y | Growth | +55.21% | -22.76% |
| CAGR | +9.20% | -5.04% | |
| Sharpe ratio | 0.34 | -0.25 | |
| Max drawdown | 18.41% | 58.96% | |
| Max daily drop | 7.59% | 6.72% | |
| Max wkly drop | 9.18% | 11.19% | |
| 10Y | Growth | +149.24% | +12.37% |
| CAGR | +9.57% | +1.17% | |
| Sharpe ratio | 0.34 | -0.02 | |
| Max drawdown | 27.37% | 58.96% | |
| Max daily drop | 10.04% | 7.73% | |
| Max wkly drop | 13.25% | 15.34% |
| Category | JNJ | PFE |
|---|---|---|
| Company | Johnson & Johnson | Pfizer Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Johnson & Johnson operates two segments: Innovative Medicine (branded pharmaceuticals including immunology, oncology, and neuroscience) and MedTech (surgical robotics, orthopedics, and cardiovascular devices). Following the Kenvue spin-off of its consumer health division, J&J is now a pure-play pharmaceutical and medical technology company. Revenue is broadly diversified across therapeutic areas and geographies. | Pfizer is a global biopharmaceutical company whose revenue base surged during COVID-19 due to its mRNA vaccine (Comirnaty) and antiviral (Paxlovid), then contracted sharply as pandemic demand normalized. The company is now executing a major post-COVID repositioning focused on oncology, rare diseases, and anti-infectives, accelerated by the $43B acquisition of Seagen. Legacy blockbusters including Eliquis and Vyndaqel anchor non-COVID revenue. |
| Investor focus | Investors track the Innovative Medicine segment's pipeline progression — particularly oncology and immunology launches replacing Stelara biosimilar erosion — alongside MedTech's surgical robotics ramp and dividend growth continuity. | Investors track the speed of non-COVID revenue recovery, Seagen oncology pipeline integration, the sustainability of the dividend given elevated debt, and whether newly launched products can offset the roughly $20B+ COVID revenue decline. |
- →Dividend King with 60+ consecutive years of dividend increases
- →Deep oncology and immunology pipeline with multiple Phase 3 assets
- →MedTech segment provides differentiated exposure to surgical robotics and cardiovascular devices
- →Seagen acquisition adds a leading oncology antibody-drug conjugate platform
- →Eliquis (blood thinner) and Vyndaqel (cardiac) provide durable non-COVID revenue
- →Deep manufacturing scale and global distribution infrastructure
- →Stelara biosimilar competition eroding a key revenue pillar
- →Ongoing talc litigation liability and settlement uncertainty
- →MedTech integration complexity following multiple acquisitions
- →Post-COVID revenue cliff creating multi-year earnings pressure
- →Elevated debt load from Seagen acquisition constraining financial flexibility
- →Multiple patent expirations creating a 'patent cliff' risk from 2025-2030
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.